Plain-English translation of NCT05765084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding —a medication that helps your immune system fight cancer—plus a personalized vaccine made from your own immune cells can work better than chemotherapy alone for pleural mesothelioma, a serious cancer linked to asbestos exposure. The study combines this new treatment with standard chemotherapy that doctors already use for this disease. The goal is to see if this combination is safe and whether it helps people live longer.
Pleural mesothelioma is a very aggressive cancer with a poor outlook—most patients survive only 9 to 16 months after diagnosis. Current chemotherapy helps somewhat, but doctors need better options. This trial is testing whether adding the medication can boost the body's own immune system to fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive four cycles of standard chemotherapy over about 12 weeks. During each cycle, you'll also receive the experimental immune medication and a personalized vaccine made from your own white blood cells. The vaccine requires a special procedure at the beginning to collect your cells (leukapheresis). After the initial four cycles, if you and your doctor agree, you may continue receiving the medication and vaccine on a monthly basis. Throughout the trial, you'll have regular blood tests and check-ups to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Belgium